Artificial intelligence is moving from the margins to the mainstream of pharmaceutical research, with a sweeping transformation already underway across drug discovery, clinical trial recruitment, and site selection.
According to a report by a global pharma professionals' body, more than half of all future approved drugs will involve AI somewhere in their development pipeline by 2030, with the shift expected to be visible in FDA approvals as early as 2026.
The investment dollars are following the ambition. Eli Lilly's venture arm has backed Abridge, a health tech startup now expanding into clinical trial recruitment and life sciences — a sign that big pharma is betting AI can solve one of the industry's most persistent bottlenecks: finding and enrolling the right patients.
On the discovery side, Viva Biotech has launched an AI-driven drug discovery platform it calls AIDD, aimed at providing end-to-end services from early-stage structure-based R&D through to commercial manufacturing — a model that collapses what traditionally required multiple specialist vendors.
Beyond the lab, AI is also changing how trials are designed and where they run. According to Pharmaphorum, AI and connected data are reshaping feasibility and site selection across the clinical development lifecycle, allowing trial sponsors to move away from fragmented, assumption-based planning toward more data-grounded decisions.
The human picture is shifting too. As Hindustan Times reports, a new breed of pharmaceutical researcher — like Patrick Schwab — works in environments with no lab benches, no bubbling liquids, and no white coats.
If these trends hold, AI won't just speed up drug development — it could fundamentally lower the cost and failure rate of bringing new medicines to patients.